A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.

Inclusion Criteria:

• Provision of written informed consent
• Previously confirmed histological diagnosis of locally advanced or metastatic hereditary medullary thyroid carcinoma without standard therapeutic options
• Aged 18 or over and a life expectancy of more than 12 weeks

Exclusion Criteria:

• The last dose of prior chemo/radiation received less than 4 weeks before the start of study therapy
• Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age, history of arrhythmia